Telomere maintenance and the etiology of adult glioma

Neuro-Oncology

Volumn 17, Issue 11, 2015, Pages 1445-1452

  Walsh, Kyle M ^a,d   Wiencke, John K ^a,b   Lachance, Daniel H ^c   Wiemels, Joseph L ^a   Molinaro, Annette M ^a   Eckel Passow, Jeanette E ^c   Jenkins, Robert B ^c   Wrensch, Margaret R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

genome wide association; glioma; shelterin; telomerase; telomere

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ARTX GENE; ASTROCYTOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DISEASE MARKER; FAMILIAL CANCER; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLIOMA; HUMAN; LEUKOCYTE TELOMERE LENGTH; LUNG FIBROSIS; MISSENSE MUTATION; OLIGODENDROGLIOMA; PENETRANCE; POT1 GENE; REVIEW; RTEL1 GENE; SOMATIC MUTATION; TELOMERE; TELOMERE HOMEOSTASIS; TERC GENE; TERT GENE; BRAIN TUMOR; GENETICS;

ADULT; BRAIN NEOPLASMS; GLIOMA; HUMANS; TELOMERE;

EID: 84946553989     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov082     Document Type: Review

References (75)

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
2. Walsh KM, Codd V, Smirnov IV, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet. 2014;46(7):731-735.
3. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41(8):905-908.
4. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009; 41(8):899-904.
5. Sanson M, Hosking FJ, Shete S, et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet. 2011;20(14): 2897-2904.
6. Stacey SN, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011;43(11):1098-1103.
7. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
8. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15):6021-6026.
9. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126(3):443-451.
10. Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194-1203.
11. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014;16(7): 896-913.
12. Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126(6):907-915.
13. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
14. Mur P, Mollejo M, Hernandez-Iglesias T, et al. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade. J Neuropathol Exp Neurol. 2015;74(3):241-249.
15. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on TERT promoter mutation, IDH mutation, and 1p/19q codeletion. N Engl J Med. 2015 (in press).
16. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97(4):503-514.
17. Shore D, Bianchi A. Telomere length regulation: coupling DNA end processing to feedback regulation of telomerase. EMBO J. 2009; 28(16):2309-2322.
18. McEachern MJ, Krauskopf A, Blackburn EH. Telomeres and their control. Annu Rev Genet. 2000;34:331-358.
19. Fitzpatrick AL, Kronmal RA, Gardner JP, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol. 2007;165(1):14-21.
20. Codd V, Mangino M, van der Harst P, et al. Common variants near TERC are associated with mean telomere length. Nat Genet. 2010; 42(3):197-199.
21. Wang C, Meier UT. Architecture and assembly of mammalian H/ACA small nucleolar and telomerase ribonucleoproteins. EMBO J. 2004;23(8):1857-1867.
22. Denham J, Nelson CP, O'Brien BJ, et al. Longer leukocyte telomeres are associated with ultra-endurance exercise independent of cardiovascular risk factors. PLoS One. 2013;8(7):e69377.
23. Huzen J, Wong LS, van Veldhuisen DJ, et al. Telomere length loss due to smoking and metabolic traits. J Intern Med. 2014;275(2): 155-163.
24. Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet. 1994;55(5):876-882.
25. Vasa-Nicotera M, Brouilette S, Mangino M, et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet. 2005;76(1):147-151.
26. Codd V, Nelson CP, Albrecht E, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013;45(4):422-427, 427e1-e2.
27. Mangino M, Hwang SJ, Spector TD, et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Hum Mol Genet. 2012;21(24): 5385-5394.
28. Nelson ND, Bertuch AA. Dyskeratosis congenita as a disorder of telomere maintenance. Mutat Res. 2012;730(1-2):43-51.
29. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(6):613-620.
30. George G, Rosas IO, Cui Y, et al. Short telomeres, telomeropathy and subclinical extra-pulmonary organ damage in patients with interstitial lung disease. Chest. 2014 [Epub ahead of print].
31. Holohan B, Wright WE, Shay JW. Cell biology of disease. Telomeropathies: an emerging spectrum disorder. J Cell Biol. 2014;205(3):289-299.
32. Wilson WR, Herbert KE, Mistry Y, et al. Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J. 2008;29(21): 2689-2694.
33. Okuda K, Bardeguez A, Gardner JP, et al. Telomere length in the newborn. Pediatr Res. 2002;52(3):377-381.
34. Weinstein BS, Ciszek D. The reserve-capacity hypothesis: evolutionary origins and modern implications of the trade-off between tumor-suppression and tissue-repair. Exp Gerontol. 2002;37(5):615-627.
35. Ma H, Zhou Z, Wei S, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One. 2011; 6(6):e20466.
36. Wentzensen IM, Mirabello L, Pfeiffer RM, et al. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1238-1250.
37. Hou L, Zhang X, Gawron AJ, et al. Surrogate tissue telomere length and cancer risk: shorter or longer? Cancer Lett. 2012;319(2): 130-135.
38. Blackburn EH. Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prev Res (Phila). 2011;4(4): 473-475.
39. Walcott F, Rajaraman P, Gadalla SM, et al. Telomere length and risk of glioma. Cancer Epidemiol. 2013;37(6):935-938.
40. Wang S, Chen Y, Qu F, et al. Association between leukocyte telomere length and glioma risk: a case-control study. Neuro Oncol. 2014;16(4):505-512.
41. Yung WK. From GWAS risk foci to glioma molecular subclass. Neuro Oncol. 2013;15(5):513-514.
42. Jenkins RB, Xiao Y, Sicotte H, et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet. 2012;44(10):1122-1125.
43. Vannier JB, Sarek G, Boulton SJ. RTEL1: functions of a diseaseassociated helicase. Trends Cell Biol. 2014;24(7):416-425.
44. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007;369(9556):107-114.
45. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(Suppl 4): iv1-i63.
46. Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42(Database issue):D1001-D1006.
47. Gansner JM, Rosas IO. Telomeres in lung disease. Transl Res. 2013; 162(6):343-352.
48. Iles MM, Bishop DT, Taylor JC, et al. The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst. 2014;106(10). doi: 10.1093/jnci/dju267.
49. Walsh KM, Rice T, Decker PA, et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro Oncol. 2013;15(8):1041-1047.
50. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985-1996.
51. Liu Y, Shete S, Etzel CJ, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol. 2010; 28(14):2467-2474.
52. Spiegl-Kreinecker S, Lötsch D, Ghanim B, et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol. 2015;17(9):1231-1240.
53. Landi MT, Chatterjee N, Yu K, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85(5):679-691.
54. Turnbull C, Rapley EA, Seal S, et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet. 2010;42(7):604-607.
55. Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant rs2736100-C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371-1374.
56. Walsh KM, Anderson E, Hansen HM, et al. Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genet Epidemiol. 2013;37(2):222-228.
57. Houlston RS, Cheadle J, Dobbins SE, et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet. 2010;42(11):973-977.
58. Speedy HE, Di Bernardo MC, Sava GP, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2014;46(1):56-60.
59. Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G.A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-525.
60. Bainbridge MN, Armstrong GN, Gramatges MM, et al. Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst. 2015;107(1):384.
61. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008;42:301-334.
62. Lei M, Podell ER, Cech TR. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat Struct Mol Biol. 2004;11(12):1223-1229.
63. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19(18):2100-2110.
64. Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet. 2014;46(5):478-481.
65. Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46(5):482-486.
66. Aoude LG, Pritchard AL, Robles-Espinoza CD, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst. 2015;107(2). doi: 10.1093/jnci/dju408.
67. Ramsay AJ, Quesada V, Foronda M, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet. 2013;45(5):526-530.
68. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286(5449): 2528-2531.
69. Tachibana I, Smith JS, Sato K, et al. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. Am J Med Genet. 2000;92(2):136-141.
70. Chang S, Khoo CM, Naylor ML, et al. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 2003;17(1):88-100.
71. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333(6041):425.
72. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122): 959-961.
73. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122): 957-959.
74. Heaphy CM, Subhawong AP, Hong SM, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011; 179(4):1608-1615.
75. Rice T, Zheng S, Decker PA, et al. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro Oncol. 2013;15(5): 535-541.